肺癌血管靶向治疗新进展.pptVIP

肺癌血管靶向治疗新进展Advances in Vessel Targeted Therapy of Lung Cancer;CONTENTS;CONTENTS;一、肺癌血管靶向治疗概述;;;CONTENTS;1. 贝伐单抗联合化疗与单用化疗治疗初治局限性或转移性NSCLC的系统回顾与meta分析1. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis ;Botrel TE et al, Lung Cancer, 2011 Mar.5;Botrel TE et al, Lung Cancer, 2011 Mar.5;CT联合贝伐单抗可以提高ORR，延长PFS。 CT联合贝伐单抗对OS的获益未明确。 接受贝伐单抗治疗组的严重血液学毒性(3度) 、中性粒细胞削减和粒缺性发热的发生更常见。;2. JO19907：卡铂+紫杉醇+贝伐单抗 vs. 卡铂+紫杉醇一线治疗日本晚期非鳞NSCLCⅡ期随机试验 2. Randomized phas